

SELL

TP: Rs 1,926 | ▼ 15%

DALMIA BHARAT

| Cement

| 23 July 2025

Realisations drive quarterly show; challenges not resolved

- Revenue remains flat YoY (-11% QoQ) to Rs 36.4bn, as volume gains took a back in a chase to improve realisations gains
- Cost stays flat YoY, largely driven by raw material cost and energy expenses saving, likely to reverse in the medium term
- Maintain earnings, introduce FY28 earnings with 13% EBITDA gains, value at 12x EV/EBITDA 1YF. Maintain SELL; TP revised to Rs 1,926

Milind Raginwar

research@bobcaps.in

Realisations driven by performance: DALBHARA's revenue remained flat YoY (-11% QoQ) at Rs 36.4bn in Q1FY26. The chase for realisations was the highlight of the quarter as volumes fell 6%19% YoY/QoQ to 7.0mt; though DALBHARA's sales (ex-JPA tolling) were flat YoY. Realisations rose 6%9% YoY/QoQ to Rs 5,194/t, driven by improved prices in the southern region (spike in prices) and stable prices in the East.

Cost stays flat; likely to reverse in medium term: Overall cost per tonne stayed flat YoY (+2.6% QoQ) at Rs 3,933/t. Power & fuel expenses (adjusted for raw material) fell ~8% YoY (-5% QoQ) to Rs 1,703/t, aided by lower fuel costs (\$100/t vs \$106/t in Q1FY25 and \$95/t in Q4FY25) and higher renewable energy (RE) usage at 41%. The blended fuel cost was Rs 1.33/kcal. Logistics cost rose 2% YoY to Rs 1,135/t, due to an 8 km increase in lead distance to 280 km; though direct dispatch improved to 62%. Other expenditure remained stable at Rs 5.4bn YoY.

EBITDA gains on a weak base: EBITDA surged 32%/11% YoY/QoQ to Rs 8.8bn, supported markedly by realisation gains. EBITDA margin improved to 24.3% vs 18.5% in Q1FY25. EBITDA/t rose ~41% YoY to Rs 1,234/t. Adjusted PAT rose 48% YoY (-13% QoQ) to Rs 3.8bn from Rs 2.5bn in Q1FY25, aided by higher EBITDA.

Growth capex to drive capacities: Q1FY26 capex was Rs 6.1bn, focused on Umrangso clinker unit and Belgaum & Pune projects. FY26 capex is planned at Rs 40bn. Umrangso clinker unit of 3.6mt nears completion, with trial runs in Q2FY26 and commercial production in Q3FY26 ramping up total clinker capacity to 27.1mt.

Introduce FY28 earnings; maintain 12x multiple; retain SELL: We maintain our FY26/FY27 EBITDA estimates, factoring DALBHARA's mix choice of realisation chase and market share. We see no major substitutes for JAL assets. We introduce FY28 earnings with 13% EBITDA growth. Our FY25-FY28 Revenue/EBITDA/PAT CAGR is penned at 11%14.9%20%. We continue to assign the stock an EV/EBITDA of 12x 1YF given the growth trajectory and healthy balance sheet (as of now) and revise our TP to Rs 1,926 (from Rs1,742) on rollover. This reflects a replacement cost (implied) of Rs 8.5bn. Maintain our SELL rating on DALBHARA.

Key changes

Target	Rating
▲	◀▶

Ticker/Price	DALBHARA IN/Rs 2,270
Market cap	US\$ 4.9bn
Free float	44%
3M ADV	US\$ 9.8mn
52wk high/low	Rs 2,343/Rs 1,601
Promoter/FPI/DII	56%/12%/8%


Source: NSE | Price as of 23 Jul 2025

Key financials

Y/E 31 Mar	FY25A	FY26E	FY27E
Total revenue (Rs mn)	1,39,800	1,57,918	1,77,654
EBITDA (Rs mn)	24,070	27,600	32,324
Adj. net profit (Rs mn)	8,120	9,412	12,314
Adj. EPS (Rs)	42.7	50.9	66.6
Consensus EPS (Rs)	42.7	59.4	71.1
Adj. ROAE (%)	4.6	5.7	7.6
Adj. P/E (x)	53.1	44.6	34.1
EV/EBITDA (x)	18.1	14.8	12.1
Adj. EPS growth (%)	(4.9)	19.0	30.8

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE



Fig 1 – Earnings call highlights

Parameters	Q1FY26	Q4FY25	Our view
Volumes and realisations	<p>Sales volumes declined 6% YoY to 7mt; Dalmia plant sales (excl. JPA tolling arrangement) were flat YoY. Revenue was flat YoY at Rs 36.4bn. Trade sales share rose to 68% (from 64% YoY); premium product mix was steady at 22%. NSR up 6%/9% YoY/QoQ on improved price positioning. Southern region saw a strong improvement in prices; eastern prices held stable, maintaining prior gains. Spot prices held their level despite an early monsoon and will likely remain firm.</p>	<p>Volumes fell by 3% YoY to Rs 8.6mn tonnes. However, sales from Dalmia plant ex-JAL grew by 4%. In FY25, growth was ~6%. Revenue witnessed 8.6% QoQ gains, driven by volume and price hike; improvement in premium product mix to 24% from 21% aided revenue and trade mix also improved to 67% from 65%. For FY25, revenue fell by 4.8% YoY on softness in prices.</p>	<p>Volume pressure from industry in 2H on a higher base and capacity addition likely to add pricing pressure. DALBHARA's focus shifting to the realisation chase will lead to MS loss.</p>
Margins	<p>RM cost up 6.4% QoQ to Rs 791/t on mineral tax imposed by Tamil Nadu government. Power and fuel costs were down 2% YoY to Rs 981/t (fuel rate \$100/t from \$106/t, blended fuel cost Rs 1.33/kcal). RE consumption increased to 41% from 39% YoY. DALBHARA commissioned 26MW of RE capacity. Logistics cost was up 2% YoY to Rs 1,135/t as lead distance rose 8 km to 280 km, but direct dispatch improved to 62%.</p>	<p>As per management's efforts to reduce cost 2.2MW solar power plant in Lanka, Assam has been added, and another 13 MW capacity is also commissioned under group captive arrangement. Fuel cost per tonne declined by 7% YoY to Rs 945/t, driven by a decline in fuel consumption cost from \$114 to \$95 and a subsequent improvement in renewable energy to 39% from 34%. Blended fuel cost fell to Rs 1.30/kcal (Rs1.31/kcal in Q3FY25). There is some volatility expected in fuel prices as spot prices are volatile and global macroeconomic uncertainties. Logistics cost declined by 2% YoY to Rs 1,135/t as direct dispatch increased from 56% in Q4FY24 to 61% Q4FY25.</p>	<p>Focus on renewable power could provide further respite in cost savings. Any announcement in Central India capacity expansion to replace the lost JAL opportunity, will help the company in long term.</p>
Capacity	<p>Cement capacity stood at 49.5mt. Umrangso clinker unit of 3.6mt is near completion, with trial runs starting in Sep'25 and commercial production starting in Q3FY26, increasing the total clinker capacity to 27.1mt. Belgaum (3.6mt clinker unit & 3mt grinding unit) and Pune (3mt grinding unit) on track for commissioning in FY27. Kadapa expansion (3.6mt clinker unit & 6mt grinding unit) with Chennai bulk terminal (3mt) has been approved at Rs 32.9bn capex. Jaisalmer 6mt greenfield expansion is under evaluation. Management targets capacity of 63.5-64mt by FY28.</p>	<p>Milestone of 49.5mnt cement capacity has been achieved. DALBHARA has commissioned a 2.4mnt grinding unit at Lank, Assam and 0.5mnt unit at Bihar. Further capacity expansion plan of 3mnt at the Belgaum plant has been announced; a new greenfield 3mnt grinding plant at Pune likely to be commissioned by FY27-end. This 6mnt capacity will mainly cater to the demand in Maharashtra.</p>	<p>At ~60% capacity utilisation, DALBHARA has enough capacity to handle incremental demand. However, as per mgmt, it is incurring capex in areas where plant capacity has high utilisation and in newer geographies. Prudent capex will only help improve further efficiencies and help maintain balance sheet.</p>
Capex	<p>Q1FY26 capex was at Rs 6.1bn, primarily for Umrangso clinker unit and Belgaum and Pune projects. For FY26 capex guidance is Rs 40bn (75-80% for growth, balance for RE/maintenance). Umrangso capex at Rs 6-8bn, Belgaum at Rs 14-16bn by FY27. For FY27 capex should be in a similar range of ~Rs 40bn. Capex will be funded via internal accruals and debt.</p>	<p>Total capex for FY25 was ~Rs 24bn; significant investments were made in ongoing projects, including expansion milestones and renewable energy projects. For FY26, mgmt has increased guidance to Rs 35bn, which will be focussed on the expansion of Belgaum plant, new plant at Pune and other future projects.</p>	<p>Prudent capex for organic and inorganic capacity addition will be key for growth. Importantly, capex addition must be without major/no stress on the balance sheet. We will keenly watch the capital allocation.</p>

Parameters	Q1FY26	Q4FY25	Our view
Other key points	<p>Gross debt was Rs 64.6bn, net debt at Rs 8.7bn (net debt/EBITDA 0.33x). Sold 370mn IEX shares, reducing stake to 10.8%. Incentives accrued were Rs 820mn, received Rs 420mn; outstanding incentive was Rs 7.8bn (incl. Rs 2.5bn from West Bengal Government). West Bengal Revocation Act (Apr'25) threatens outstanding incentives, but legal challenge has been filed. Income Tax case (FY2010-11) is under interim stay at Supreme Court. Provisional Kadapa limestone attachment (417 hectares) is deemed unsustainable and has been challenged; management does not foresee any operational risk arising from it.</p>	<p>Gross debt stood at Rs 52.8bn - an increase of Rs 6.3bn vs March '24. Net debt as of March '25 was Rs 7.16bn. Resultant net debt to EBITDA ratio stands at 0.3x.</p> <p>In April 2025, a provisional attachment order amounting to Rs 7.9bn was issued by Pune authorities. This stems from a case originally registered by the CBI in 2011, involving allegations related to the company's investments in Bharti Cement. DALBHARA clarified the order does not impact running operations, plans to take appropriate legal steps to defend their position.</p> <p>During the quarter, the company accrued Rs 0.9bn in incentives. Total incentive accruals for FY25 were Rs 33.6bn. Collections against these accruals were about Rs 30.7bn.</p>	<p>DALBHARA must maintain balance sheet health with its expansion needs. With major capex expected in FY27E/ FY28E, balance sheet could be impacted.</p> <p>ED provisional attachment is a key negative in our view and will have a negative bearing.</p>

Source: Company, BOBCAPS Research

Fig 2 – Key metrics

	1QFY26	1QFY25	YoY (%)	4QFY25	QoQ (%)	1QFY26E	Deviation (%)
Volumes (mn mt)	8.6	8.8	(2.3)	6.7	28.4	8.8	(2.8)
Cement realisations (Rs/t)	4,757	4,895	(2.8)	4,748	0.2	4,748	0.2
Operating costs (Rs/t)	3,835	4,151	(7.6)	3,985	(3.8)	3,871	(0.9)
EBITDA/t (Rs)	895	717	24.9	736	21.7	850	5.4


Source: Company, BOBCAPS Research

Fig 3 – Quarterly performance

(Rs mn)	1QFY26	1QFY25	YoY (%)	4QFY25	QoQ (%)	1QFY26E	Deviation (%)
Net Sales	36,360	36,210	0.4	40,910	(11.1)	38,497	(5.6)
Expenditure							
Change in stock	(1,010)	(800)	26.3	1,420	(171.1)	(551)	
Raw material	5,680	5,790	(1.9)	6,240	(9.0)	5,722	(0.7)
purchased products	0	0		0		0	
Power & fuel	7,250	7,570	(4.2)	7,730	(6.2)	6,993	3.7
Freight	7,950	8,300	(4.2)	9,720	(18.2)	9,071	(12.4)
Employee costs	2,270	2,280	(0.4)	2,150	5.6	2,430	(6.6)
Other exp	5,390	5,320	1.3	5,720	(5.8)	5,799	(7.0)
Total Operating Expenses	27,530	28,460	(3.3)	32,980	(16.5)	29,464	(6.6)
EBITDA	8,830	7,750	13.9	7,930	11.3	9,033	(2.3)
EBITDA margin (%)	24.3	21.4	288bps	19.4	490bps	23.5	82bps
Other Income	490	500	(2.0)	930	(47.3)	495	(1.0)
Interest	1,080	950	13.7	1,050	2.9	1,111	(2.8)
Depreciation	3,220	3,170	1.6	3,140	2.5	3,241	(0.6)
PBT	3,930	1,410	178.7	4,350	(9.7)	4,097	(4.1)
Non-recurring items	(160)	1,130	0.0	0	0	0	
PBT (after non-recurring items)	3,770	2,540	48.4	4,350	(13.3)	4,097	(8.0)
Tax	1,230	490	151.0	280	339.3	1,035	18.8
Reported PAT	3,950	1,450	172.4	4,390	(10.0)	4,141	(4.6)
Adjusted PAT	3,770	2,540	48.4	4,350	(13.3)	4,097	(8.0)
NPM (%)	10.4	7.0	335bps	10.6	(26bps)	10.6	(27bps)
Adjusted EPS (Rs)	20.4	13.7	48.4	23.5	(13.3)	22.1	(8)


Source: Company, BOBCAPS Research

Fig 4 – Price focus keeps volume subdued




Source: Company, BOBCAPS Research

Fig 5 – Strong recovery in Southern region supports prices




Source: Company, BOBCAPS Research

Fig 6 – Realisation gains boosts EBITDA/tn




Source: Company, BOBCAPS Research

Fig 7 – Operating cost challenges may emanate in medium term




Source: Company, BOBCAPS Research

Fig 8 – Freight cost inflates on account of increase in lead distance



Source: Company, BOBCAPS Research

Fig 9 – Green energy initiatives may help fuel cost savings



Source: Company, BOBCAPS Research

Valuation Methodology

We maintain our earlier stance that DALBHARA's drive to add market share through expansion will likely receive a setback with limited alternatives for the Jaiprakash Associates (JAL) assets in Central India. The company has been mixing its stance of market share and realisation chase in the recent past, which may lead to loss of markets in certain regions.

We believe this, coupled with a focus on capacity expansion from FY26-FY27 for the first leg of major capacity addition, may put some pressure on the balance sheet in the medium term; as is reflected with the addition of net debt. Capacity addition in the North East India will contribute fully in FY27; DALBHARA is unlikely to disturb pricing in the region, as the capacity will match demand in the region with many companies planning to enter the region, making it less lucrative. While cost-saving plans are in place, we feel this could raise additional concerns for DALBHARA.

Most active regions for DALBHARA are in the East (44% volume contribution with new capacity addition) and South (28% volume contribution). They are vulnerable on account of excess supply. Given the changed dynamics with two major cement groups acquiring mid-/large-size companies, supply pressure is likely to increase.

We maintain our FY26/FY27 EBITDA estimates, factoring DALBHARA's mix choice of realisation chase and market share. However, PAT estimates change due to revised depreciation provision (lower) in FY26/FY27 and hence, EPS also changes. We see no major substitutes for JAL assets. We introduce FY28 earnings with 13% EBITDA growth. Our FY25-FY28 Revenue/EBITDA/PAT CAGR is penned at 11%14.9%20%. We continue to assign an EV/EBITDA of 12x 1YF, given the growth trajectory and healthy balance sheet (as of now). We revise our TP to Rs 1,926 (from Rs1,742) on rollover. This reflects a replacement cost (implied) of Rs 8.5bn. Maintain SELL.

Fig 10 – Revised estimates

(Rs mn)	New			Old			Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	1,57,918	1,77,654	1,88,570	1,57,942	1,77,680		0.0	0.0	0.0
EBITDA	27,600	32,324	36,410	27,606	32,332		0.0	0.0	0.0
Adj PAT	9,412	12,314	14,202	7,707	10,404		22.1	18.4	0.0
Adj EPS (Rs)	50.9	66.6	76.8	41.7	56.2		22.0	18.4	0.0

Source: BOBCAPS Research

Fig 11 – Key assumptions

	FY25	FY26E	FY27E	FY28E
Volumes (mt)	29.2	32.2	36.0	37.8
Realisations (Rs/t)	4,765	4,789	4,813	4,861
Operating costs (Rs/t)	3,958	4,052	4,034	4,023
EBITDA/t (Rs/t)	823	858	897	963

Source: Company, BOBCAPS Research

Fig 12 – Valuation summary

Business (Rs mn)	FY27E
Target FY27E EV/EBITDA (x)	12.0
EBITDA (FY27E)	33,346
Target EV	4,00,149
Total EV	4,00,149
Net debt (FY27E)	43,756
Target market capitalisation	3,563,93
Target price (Rs/sh)	1,926
Weighted average shares (mn)	185

Source: BOBCAPS Research | Valuation and TP based on June 2027 earnings

Fig 13 – Peer comparison

Ticker	Rating	TP (Rs)	EV/EBITDA (x)			EV/tonne (US\$)			ROE (%)			ROCE (%)		
			FY25	FY26E	FY27E	FY25	FY26E	FY27E	FY25	FY26E	FY27E	FY25	FY26E	FY27E
DALBHARA IN	SELL	1,926	16.5	14.2	12.6	104	109	110	5.7	7.6	8.2	6.6	8.1	8.5
SRCM IN	SELL	26,974	24.8	23.5	19.4	140.6	140	121.6	4.9	8	10.6	6.7	10.5	13.4
ACC IN	HOLD	2,282	15.4	9.3	7.8	110.6	101.2	90.9	8.2	11.5	13.3	9.7	13.9	15.7


Source: Company, BOBCAPS Research

Fig 14 – EV/EBITDA band: Valuations ahead of earnings




Source: Company, Bloomberg, BOBCAPS Research

Fig 15 – EV/EBITDA 1YF: Valuations will converge to mean in the medium term




Source: Company, Bloomberg, BOBCAPS Research

Fig 16 – EV/tonne: Replacement cost reflects earnings pain



Source: Company, Bloomberg, BOBCAPS Research

Fig 17 – EV/tonne 1YF: Valuations unlikely to rebound in a hurry



Source: Company, Bloomberg, BOBCAPS Research

Key risks

Key upside risks to our estimates:

- Lower-than-expected fuel cost inflation
- Faster addition of capacity
- Faster-than-expected market recovery and strong demand pickup could reverse prices higher leading to better earnings

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Total revenue	1,46,910	1,39,800	1,57,918	1,77,654	1,88,570
EBITDA	26,390	24,070	27,600	32,324	36,410
Depreciation	(14,980)	(13,310)	(13,976)	(14,604)	(16,065)
EBIT	14,560	13,290	16,718	21,063	23,788
Net interest inc./(exp.)	(3,860)	(3,990)	(4,511)	(4,979)	(5,328)
Other inc./(exp.)	3,150	2,530	3,093	3,343	3,443
Exceptional items	0	(1,130)	0	0	0
EBT	10,700	8,170	12,207	16,084	18,460
Income taxes	(2,160)	(1,180)	(2,551)	(3,327)	(3,802)
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	(243)	(443)	(456)
Reported net profit	8,540	6,990	9,412	12,314	14,202
Adjustments	0	(1,130)	0	0	0
Adjusted net profit	8,540	8,120	9,412	12,314	14,202

Balance Sheet

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Accounts payables	20,280	23,220	25,647	27,373	27,974
Other current liabilities	21,130	16,770	21,068	20,048	19,078
Provisions	3,450	4,280	4,708	5,179	5,697
Debt funds	49,610	61,571	65,537	74,667	84,960
Other liabilities	16,480	18,550	19,824	20,581	21,439
Equity capital	380	380	370	370	370
Reserves & surplus	1,64,710	1,75,880	1,62,068	1,72,247	1,84,129
Shareholders' fund	1,66,105	1,77,520	1,63,216	1,73,462	1,85,344
Total liab. and equities	2,77,055	3,01,911	3,00,000	3,21,310	3,44,492
Cash and cash eq.	44,540	46,020	24,555	30,779	41,601
Accounts receivables	8,360	8,890	10,218	11,695	12,609
Inventories	12,180	13,860	15,695	17,424	18,235
Other current assets	24,870	27,170	29,220	31,441	33,849
Investments	5,900	6,730	7,403	8,903	10,403
Net fixed assets	1,07,626	1,20,680	1,19,827	1,18,974	1,18,121
CWIP	21,887	24,970	37,268	43,603	47,964
Intangible assets	51,692	53,590	55,815	58,492	61,711
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	2,77,055	3,01,910	3,00,000	3,21,310	3,44,492

Cash Flows

Y/E 31 Mar (Rs mn)	FY24A	FY25A	FY26E	FY27E	FY28E
Cash flow from operations	26,625	18,646	23,604	19,997	22,264
Capital expenditures	(23,220)	(32,721)	(24,403)	(18,893)	(17,459)
Change in investments	(9,380)	(6,550)	24,327	(12,000)	(11,000)
Other investing cash flows	0	0	0	0	0
Cash flow from investing	(32,600)	(39,271)	(76)	(30,893)	(28,459)
Equities issued/Others	5	245	(735)	(376)	(456)
Debt raised/repaid	9,810	11,961	3,966	9,130	10,294
Interest expenses	0	0	0	0	0
Dividends paid	(1,690)	(1,665)	(1,850)	(2,035)	(2,220)
Other financing cash flows	820	5,845	(21,374)	(100)	(100)
Cash flow from financing	8,945	16,386	(19,993)	6,619	7,518
Chg in cash & cash eq.	2,970	(4,240)	3,535	(4,277)	1,322
Closing cash & cash eq.	44,540	46,021	24,555	30,779	41,601

Per Share

Y/E 31 Mar (Rs)	FY24A	FY25A	FY26E	FY27E	FY28E
Reported EPS	44.9	36.8	50.9	66.6	76.8
Adjusted EPS	44.9	42.7	50.9	66.6	76.8
Dividend per share	8.9	8.8	10.0	11.0	12.0
Book value per share	874.2	934.3	882.3	937.6	1,001.9

Valuations Ratios

Y/E 31 Mar (x)	FY24A	FY25A	FY26E	FY27E	FY28E
EV/Sales	2.9	3.1	2.6	2.2	2.0
EV/EBITDA	16.1	18.1	14.8	12.1	10.4
Adjusted P/E	50.5	53.1	44.6	34.1	29.6
P/BV	2.6	2.4	2.6	2.4	2.3

DuPont Analysis

Y/E 31 Mar (%)	FY24A	FY25A	FY26E	FY27E	FY28E
Tax burden (Net profit/PBT)	79.8	85.6	79.1	79.3	79.4
Interest burden (PBT/EBIT)	73.5	70.0	73.0	76.4	77.6
EBIT margin (EBIT/Revenue)	9.9	9.5	10.6	11.9	12.6
Asset turnover (Rev./Avg TA)	55.2	48.3	52.5	57.2	56.6
Leverage (Avg TA/Avg Equity)	1.6	1.7	1.8	1.8	1.9
Adjusted ROAE	5.3	4.6	5.7	7.6	8.2

Ratio Analysis

Y/E 31 Mar	FY24A	FY25A	FY26E	FY27E	FY28E
YoY growth (%)					
Revenue	8.5	(4.8)	13.0	12.5	6.1
EBITDA	13.9	(8.8)	14.7	17.1	12.6
Adjusted EPS	31.5	(4.9)	19.0	30.8	15.3
Profitability & Return ratios (%)					
EBITDA margin	18.0	17.2	17.5	18.2	19.3
EBIT margin	9.9	9.5	10.6	11.9	12.6
Adjusted profit margin	5.8	5.8	6.0	6.9	7.5
Adjusted ROAE	5.3	4.6	5.7	7.6	8.2
ROCE	6.5	5.4	6.6	8.1	8.5
Working capital days (days)					
Receivables	21	23	24	24	24
Inventory	30	36	36	36	35
Payables	61	73	72	69	67
Ratios (x)					
Gross asset turnover	0.6	0.5	0.6	0.6	0.6
Current ratio	2.0	2.2	1.5	1.7	2.0
Net interest coverage ratio	3.8	3.3	3.7	4.2	4.5
Adjusted debt/equity	0.3	0.3	0.4	0.4	0.5

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**

Logo:  **BOBCAPS**
TRUST | INNOVATION | EXCELLENCE

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): DALMIA BHARAT (DALBHARA IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom (“UK”):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.